An anonymous reader sends this excerpt from The New Yorker: In April, [Dr. Eytan Stein] presented his findings to a packed auditorium at the annual meeting of the American Association for Cancer Research, in San Diego. It was the first public airing of the results of AG-221; patients with progressive [acute myelogenous leukemia] had never improved so quickly and definitively. ... The breakthrough is notable in part for the unconventional manner in which the drug attacks its target. There are many kinds of cancer, but treatments have typically combated them in one way only: by attempting to destroy the cancerous cells. Surgery aims to remove the entire growth from the body; chemotherapy drugs are toxic to the cancer cells; radiation generates toxic molecules that break up the cancer cells' DNA and proteins, causing their demise. A more recent approach, immunotherapy, co-opts the body's immune system into attacking and eradicating the tumor. The Agios drug, instead of killing the leukemic cells — immature blood cells gone haywire — coaxes them into maturing into functioning blood cells. Cancerous cells traditionally have been viewed as a lost cause, fit only for destruction. The emerging research on A.M.L. suggests that at least some cancer cells might be redeemable: they still carry their original programming and can be pressed back onto a pathway to health.